# International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

> **NCT07476729** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Charite University, Berlin, Germany** · enrollment: 750 (estimated)

## Conditions studied

- B-Cell Acute Lymphoblastic Leukaemia

## Interventions

- **DRUG:** Inotuzumab ozogamicin (INO)
- **DRUG:** Blinatumomab

## Key facts

- **NCT ID:** NCT07476729
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2033-03-31
- **Final completion:** 2033-03-31
- **Target enrollment:** 750 (ESTIMATED)
- **Last updated:** 2026-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07476729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07476729, "International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07476729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*